Drug Profile
Research programme: dendritic cell vaccines - Sotio
Alternative Names: DCVACLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator SOTIO
- Class Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for research development in Autoimmune-disorders in Czech Republic
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Czech Republic (SC, Injection)
- 13 Jun 2016 Research programme: dendritic cell vaccines - Sotio is available for licensing as of 01 Sep 2015. http://www.sotio.com/